143 related articles for article (PubMed ID: 21796719)
1. Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC).
Geier JL; Karayal ON; Lewis M; Camm JA; Keane M; Kremer CM; Kolluri S; Reynolds R; Eng S; Strom BL
Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1192-8. PubMed ID: 21796719
[TBL] [Abstract][Full Text] [Related]
2. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).
Strom BL; Eng SM; Faich G; Reynolds RF; D'Agostino RB; Ruskin J; Kane JM
Am J Psychiatry; 2011 Feb; 168(2):193-201. PubMed ID: 21041245
[TBL] [Abstract][Full Text] [Related]
3. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics.
Strom BL; Faich GA; Reynolds RF; Eng SM; D'Agostino RB; Ruskin JN; Kane JM
J Clin Psychiatry; 2008 Jan; 69(1):114-21. PubMed ID: 18312045
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia.
Kolitsopoulos FM; Strom BL; Faich G; Eng SM; Kane JM; Reynolds RF
Contemp Clin Trials; 2013 Mar; 34(2):239-47. PubMed ID: 23246610
[TBL] [Abstract][Full Text] [Related]
6. Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial.
Fleischhacker WW; Kane JM; Geier J; Karayal O; Kolluri S; Eng SM; Reynolds RF; Strom BL
J Clin Psychiatry; 2014 Mar; 75(3):e184-90. PubMed ID: 24717389
[TBL] [Abstract][Full Text] [Related]
7. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
9. Methodological concerns in a trial of ziprasidone and olanzapine.
Ross DE
Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
[No Abstract] [Full Text] [Related]
10. Methodological concerns in a trial of ziprasidone and olanzapine.
Carnahan RM; Perry PJ
Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
[No Abstract] [Full Text] [Related]
11. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
12. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
San L; Arranz B; Perez V; Safont G; Corripio I; Ramirez N; Dueñas R; Alvarez E
Psychiatry Res; 2012 Dec; 200(2-3):693-701. PubMed ID: 22954905
[TBL] [Abstract][Full Text] [Related]
13. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
[TBL] [Abstract][Full Text] [Related]
14. What can large simple trials do for psychiatry?
Stroup TS
Am J Psychiatry; 2011 Feb; 168(2):117-9. PubMed ID: 21297045
[No Abstract] [Full Text] [Related]
15. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
[TBL] [Abstract][Full Text] [Related]
16. Drug safety evaluation of ziprasidone.
Citrome L
Expert Opin Drug Saf; 2011 May; 10(3):437-48. PubMed ID: 21332416
[TBL] [Abstract][Full Text] [Related]
17. [What Lessons Should We Learn from the Death of Patients on Xeplion?].
Fujii Y
Seishin Shinkeigaku Zasshi; 2015; 117(2):132-45. PubMed ID: 26514053
[TBL] [Abstract][Full Text] [Related]
18. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
Citrome L; Yang R; Glue P; Karayal ON
Schizophr Res; 2009 Jun; 111(1-3):39-45. PubMed ID: 19375893
[TBL] [Abstract][Full Text] [Related]
19. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia.
van Veelen NM; Grootens KP; Peuskens J; Sabbe BG; Salden ME; Verkes RJ; Kahn RS; Sitskoorn MM
Schizophr Res; 2010 Jul; 120(1-3):191-8. PubMed ID: 20493663
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE;
Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
